The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Health CareSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the healthcare sector of the U.S. equity market. Component companies include, among others, health care providers, biotechnology companies, medical supplies, advanced medical devices and pharmaceuticals. The fund is non-diversified.
Inception Date: 30/01/2007
Primary Benchmark: DJ US Health Care TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 1.06%
Management Expense Ratio: 0.95 %
|FAS||Direxion Financial Bull 3X Sha..||0.00 %||
|SSO||ProShares Ultra S&P500||0.90 %||
|QLD||ProShares Ultra QQQ||0.95 %||
|TNA||Direxion Small Cap Bull 3X Sha..||0.95 %||
|UPRO||ProShares UltraPro S&P 500||0.95 %||
|SPXL||Direxion Daily S&P 500 Bull 3X..||0.95 %||
|UYG||ProShares Ultra Financials||0.95 %||
|NUGT||Direxion Daily Gold Miners Ind..||0.90 %||
|SOXL||Direxion Daily Semiconductor B..||0.95 %||
|UDOW||ProShares UltraPro Dow30||0.95 %||
|Market Performance vs.
Industry/Classification (Trading--Leveraged Equity)
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||29.24%||60%||D-||20%||F|
|Risk Adjusted Return||98.98%||79%||C+||79%||C+|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The company has under performed its peers on annual average total returns in the past 5 years.